Protocol Details
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
This study is currently recruiting participants.
Summary
Number | 09-C-0161 |
Sponsoring Institute | National Cancer Institute (NCI) |
Recruitment Detail | Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Gene Therapy;
Follow-Up;
Delayed Toxicity;
Natural History |
Recruitment Keyword(s) | Adenocarcinoma;
Melanoma;
Neuroendocrine Tumors;
Carcinoma;
Follow-Up |
Condition(s) | Melanoma;
Adenocarcinoma;
Carcinoma NOS;
Neuroendocrine Tumors |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Cancer Institute |
Background:
The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.
Objective:
This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA.
Eligibility:
Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol
Design
Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
Eligibility
INCLUSION CRITERIA:
-Age greater than or equal to 18 years.
-Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).
-For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
EXCLUSION CRITERIA:
-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT00923026Protocol Details
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
This study is currently recruiting participants.
Summary
Number | 09-C-0161 |
Sponsoring Institute | National Cancer Institute (NCI) |
Recruitment Detail | Type: Enrolling by Invitation
Gender: Male & Female
Min Age: 18 Years
Max Age: N/A |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Gene Therapy;
Follow-Up;
Delayed Toxicity;
Natural History |
Recruitment Keyword(s) | Adenocarcinoma;
Melanoma;
Neuroendocrine Tumors;
Carcinoma;
Follow-Up |
Condition(s) | Melanoma;
Adenocarcinoma;
Carcinoma NOS;
Neuroendocrine Tumors |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Cancer Institute |
Background:
The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from participants' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.
Objective:
This study will allow participants to be followed for up to 15 years following treatment on an NCI Surgery Branch Gene Therapy Trial as required by the FDA.
Eligibility:
Participants must have been enrolled on an NCI Surgery Branch Gene Therapy Protocol
Design
Participants will be followed with a physical examination and blood tests for up to 15 years as required by the FDA
Eligibility
INCLUSION CRITERIA:
-Age greater than or equal to 18 years.
-Participants who have received treatment on an NCI-SB protocol, including gene therapy protocols. (Note: Participants may be enrolled on this protocol and, at the same time, participate in an active treatment study).
-For Cohort A:Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. For Cohort B: Participant is able to provide informed consent.
EXCLUSION CRITERIA:
-For Cohort B: Individuals of child-bearing potential (IOCBP) who are pregnant or plan to become pregnant because of the potentially dangerous effects of the investigational treatments administered on NCI-SB treatment protocols.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT00923026